26474 Antimicrobial Susceptibility Panel, Yeast, Varies (MMLYP)

​​Abelcet (Amphotericin B); Amphotericin B (Abelcet); Anidulafungin (ERAXIS); CANCIDAS (Caspofungin); Caspofungin (CANCIDAS); Diflucan (Fluconazole); ERAXIS (Anidulafungin); Fluconazole (Diflucan); Itraconazole (Sporanox); Micafungin (Mycamine); NOXAFIL (Posaconazole); Posaconazole (NOXAFIL); Sporanox (Itraconazole); Susceptibility Panel, Yeast; Susceptibility Testing; Vfend (Voriconazole); Voriconazole (Vfend); Yeast Susceptibility Panel; Isavuconazole (Cresemba); Rezafungin (Rezzayo); Rezzayo (Rezafungin)

Antifungals included in the assay are amphotericin B, anidulafungin, caspofungin, fluconazole, itraconazole, isavuconazole, rezafungin, micafungin, posaconazole, and voriconazole.

When this test is ordered, the Susceptibility Yeast Panel will be performed at an additional charge. All yeast submitted will have susceptibility testing performed and billed as appropriate.

Determining in vitro quantitative antifungal susceptibility (minimum inhibitory concentration) of non-fastidious yeast

As an aid in the management of certain circumstances, such as:

-Refractory oropharyngeal infections due to Candida species in patients who appear to be experiencing therapeutic failure with standard agents at standard doses

-Invasive infections due to Candida species when the utility of azole antifungal agents is uncertain (eg, when the infection is due to a non-Candida albicans organism)

​Specimen source and suspected organism identification are required. If identification of organism is not provided, FUNID / Culture Referred for Identification, Fungus, Varies will be performed at an additional charge.

Organism must be in pure culture, actively growing. Do not submit mixed cultures.

​The assay cannot be used for minimum inhibitory concentration determinations for the dimorphic yeast or filamentous fungi.

​Candida species are the fourth leading cause of nosocomial infections and are frequent causes of community-acquired infections.

Antifungal susceptibility testing may aid in the management of patients with invasive infections due to Candida species or patients who appear to be experiencing therapeutic failure.

The Clinical Laboratory Standards Institute has approved the use of a broth microdilution method for determining the susceptibility of Candida species.

​The Clinical and Laboratory Standards Institute method, breakpoints, and interpretive criteria are used.